Komori
Earnings2531TAKARA HOLDINGS INC.Food

Results of the investigation into the accounting treatment of our consolidated subsidiary Takara Bio USA, Inc.

The investigation into Takara Bio USA's accounting treatment identified immaterial misstatements, but found no intentional improper accounting or material impact on the consolidated financial statements. It was determined that restatement of prior-year consolidated financial statements was unnecessary, and an unmodified interim review report was received for the quarterly consolidated financial statements for the first quarter of the fiscal year ending March 2027.

Worth reading
—
Scored from 0 of 6 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Results for this period

First quarterConsolidated
Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Consolidated / non-consolidatedConsolidated
Items this document does not state (36)
Accounting standardsPeriod CoveredNet SalesOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-EndFactors Behind Changes in Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

An external team of specialists, including legal experts and certified public accountants, and an internal investigation team conducted interviews with relevant parties, digital forensics and reviews of related materials. As a result, no circumstances with a material impact or intentional improper accounting were identified.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Results of the investigation into the accounting treatment of our consolidated subsidiary Takara Bio USA, Inc. | TAKARA HOLDINGS INC. (2531) timely disclosure | Komori